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Abstract 
Introduction: The results of experimental and clinical trials make it clear that incretin mimetics 
possess pleiotropic effects and demonstrate the value in terms of assessment of their potential 
opportunities as cardioprotectors. 
Goals: To study the cardioprotective effects of exenatide and vildagliptin on the model of 
doxorubicin-induced cardiomyopathy.  
Methods:  The experiments on the Langendorf isolated rat heart were dedicated to the study of 
cardioprotactive activity of exenatide (10 mcg/kg/day) («Byetta®», Eli Lilly and Company, USA) 
and vildagliptin (0.2 mg/kg/day) («Galvus®», Novartis, Switzerland), on the contractile function 
of the isolated heart wich was previously perfused with doxorubicin (20 mg/kg, intraperitoneally 
before 48 hours). The evaluation of cardioprotactive activity was based on the findings of the 
functional trial with high-frequency stimulation (480 bmp) in hypercalcium (5 mmol) perfusion.  
The complex evaluation of the myocardial damage in the flowing perfusate from isolated hearts 
included the assessment of creatine phosphokinase isoenzyme (CPK-MB) and lactic 
dehydrogenase (LDH). The activity of lipid peroxidation (LPO) was evaluated by measuring the 
content of malondialdehyde (MDA) and diethenoid conjugant (DC).  
Results: Exenatide (10 mcg/kg/day) and vildagliptin (0.2 mg/kg/day) demonstrate a cardioprotactive 
effect on the model of doxorubicin-induced pathology, resulting in a decrease of diastolic dysfunction 
to 5.3±0.1 units and 6.5±0.2 units respectively, compared to control 8.3±0.1 units. 
The cardioprotactive effect was confirmed by 45% and 30% decrease in the levels of CPK-MB 
marker damage, and by  36%  and  24%  decrease  in  LDH  levels respectively in exenatide and 
vildagliptin series, compared to control. The cardioprotactive effect was also confirmed by prevention 
of accumulation of lipid peroxidation products of MDA and DC in the ventricular myocardium.  
 Conclusion: Exenatide (10 mcg/kg/day) and vildagliptin  (0.2 mg/kg/day) decrease diastolic 
disfunction, resulting in the recovery of the contractile function of the heart, reduction of the 
“diastole defect” (StТТI), and the decrease in irreversible damages of cardiomyocytes.  
Key words: incritinomimetics; exenatide; vildagliptin; doxorubicin-induced cardiomyopathy; 
isolated rat heart. 
Introduction. 
New substances with cardiotropic effects are 
being identified among various classes of chemical 
and pharmacological groups [1, 2, 3, 4, 5, 6, 7, 8]. 
Undoubted interest is represented by incretin 
mimetics , as a fairly new group of hypoglycemic 
agents with pleiotropic effects, in particular, 
cardioprotective [9, 10, 11, 12]. The exact 
mechanisms underlying the effect of GLP-1 on the 
cardiac muscle have not yet been established [13, 14, 
15]. It is suggested that GLP-1 can positively 
influence the apoptosis of cardiomyocytes, oxidative 
stress, and endogenous antioxidant defense 
mechanisms, having a beneficial effect on 
cardioprotection of the myocardium [16, 17, 18, 19]. 
The formation of free radicals leads to an 
increase in oxidative stress, the triggering of 
apoptosis-mediated through iron ions calcium, NO-
oxidase, glutathione peroxidase, neuregulin-1, 
protein kinase B, growth factors, cytokines and their 
Rus. 
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receptors, which may be a direct cause of 
doxorubicin-induced cardiomyopathy. The theory of 
oxidative stress in the development of doxorubicin-
induced cardiopathy is the most popular, and often 
serves as an experimental model for studying the 
causes of apoptotic cell death and the selection of 
means for cardioprotection [20, 21]. 
Goals: To study the cardioprotective effects of 
exenatide and vildagliptin on the model of 
doxorubicin-induced cardiomyopathy. 
Methods. 
The experiments were carried out on 40 mature 
Wistar rats of both sexes weighing 220 ± 20 g. All 
animal manipulations were carried out in compliance 
with the "European Convention for the Protection of 
Vertebrates used for Experiment or Other Scientific 
Purposes" [Derective 2010/63/ EU]. All experiments 
were approved by the local Ethics Committee 
(Minutes No. 12-2016 of November 21, 2016). 
All rats were divided into 4 experimental groups 
of 10 animals. The first group (n = 10), control, was 
intraperitoneally injected a saline solution. The 
second group (n = 10) was intraperitoneally injected 
with doxorubicin (Teva) at a cumulative dose of 20 
mg/kg, once, the third (n = 10) – doxorubicin and 
intraperitoneal vildagliptin ("Galvus®", Novartis, 
Switzerland) at a dose of 0.2 mg/kg/day. The fourth 
(n = 10) – doxorubicin and exenatide ("Byetta®", Eli 
Lilly and Company, USA) subcutaneously once a day 
at a dosage of 10 mcg/kg/day. The doses of the drugs 
were calculated taking into account the coefficient of 
interspecific transfer of doses from the human body 
to the body of a rat. 
The animals were withdrawn from the 
experiment after 48 hours. The hearts were removed 
from the animals under zolestal anesthesia     
(30 mg/kg) and placed in an icy (2-4°C) Krebs-
Henselite solution of the following composition 
(mmol): NaCl – 118.5; KCl – 4.7; MgSO4/7H2O – 
1.2; KH2PO4 – 1.2; CaCl2 – 1.5; Glucose – 11.1; 
NaHCO3 – 25.0. The pH level of the solution 
throughout the experiment was 7.4. After the 
termination of spontaneous contractions, the aorta 
was isolated and the connective tissue was separated. 
The aorta was then cannulated and retrograde 
perfusion of the heart was performed using the 
Langendorff method in a flow perfusion mode for          
20 min with the Krebs-Henselite solution, saturated 
with carbogen (95% O2 + 5% CO2) at 37° C and           
100 mmHg pressure and perfusate speed 10 ml/min. 
The cardiac contractility was recorded with a 
latex balloon inserted into the left ventricle cavity 
and connected to a pressure sensor built into the 
device for physiological studies of the MP150 of 
BiopacSystems, Inc. (California, USA). The can was 
filled with distilled water, the volume of which was 
sufficient to create a diastolic pressure in the left 
ventricle at a level of 3-5 mm Hg. With the help of 
the original AcqKnowledge application of the 
company "BiopacSystems, Inc." (California, USA), 
the contractility indices in the rats were recorded: left 
ventricular pressure (LVP, mmHg), heart rate (HR, 
bpm). The maximum rate of contraction (+dp/dtmax, 
mmHg/sec), the maximum relaxation rate of the 
myocardium (-dp/dtmax, mmHg/sec). To create a high 
frequency (480 bpm) a connector-ground of an 
electric stimulator was attached to the metallized 
cannula, and a connector-plus was attached to the eye 
of the left atrium. After 20 minutes of perfusion with 
a high Ca
2+
 (5 mmol / L) solution, the heart was 
stimulated with electrical pulses using the STM 
200-1 device from BiopacSystems, Inc. (California, 
USA) for 15 seconds. 
To assess the functionality of the myocardium, 
the diastolic dysfunction ratio or "diastole defect" 
(StTTI) calculated from the intraventricular pressure 
curve was used. The area under the curve was 
calculated by folding the trapezium areas, which is 
equal to the product of its height on the middle line. 
The "diastole defect" (StTTI) was expressed in units. 
The cardioprotective effects of the drugs vildagliptin 
and exenatide were judged by their effect on the StTTI 
index [22]. The damage markers and the level of 
peroxidation were evaluated by conventional 
methods [23, 24]. 
The reliability of changes in absolute parameters 
was determined by the difference method of 
variational statistics with finding the mean values of 
the shifts, the mean of the arithmetic mean, and the 
probability of possible error (p) from Student's tables. 
Differences between the values of the indices were 
considered statistically significant at p <0.005. 
Results. 
Doxorubic myocardiopathy was characterized 
by a decrease in myocardial contractility (Table 1). 
Conducting a functional test with high-frequency 
stimulation revealed the development of the "diastole 
defect" (Fig. 1a), and StТТI increased to 8.3 ± 0.3 units 
in comparison with intact animals – 1.4 ± 0.1 units, 
in other words, it increased 8 times. 
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а       b 
Fig. 1. Exercise tolerance test under submaximal electrical stimulation of a rat heart isolated by Langendorf. Са2+ concentration 
in perfusate – 5 mmol/L. Intact group.Pressure profile in the left ventricle (mmHg) at imposing qickened heartbeat (480 bpm) 
within 15 sec. Са2+ concentration in perfusate – 5 mmol/L. Doxorubicin (20 mg/kg ) given at a single dose within 48 hours (а). 
Intact group (b) 
The incretin mimetics  of exenatide in doses 
(1.0 mg/kg/day and 10 mcg/kg/day) and vildagliptin 
(0.02 and 0.2 mg/kg/day) did not affect the degree of 
decrease in contractility rates (as reflected in the 
Table) and dose-dependently prevented a decrease in 
contractility when carrying out the test with high-
frequency stimulation. Thereat, StTTI for exenatide 
10 mg/kg/day and vildagliptin 0.2 mg/kg/day were 
5.3 ± 0, 16.5 ± 0.2 units respectively.  
Table 1 
Effects of incretin mimetics  exenatide and vildagliptin on indices of contractile function 
/of the heart of rats with doxorudicine cardiomyopathy (M ± m; n = 10). 
Groups of animals LVP +dp/dtmax -dp/dtmax HR 
Intact animals 87.3±9.2* 1423±162.2* -1265.2±173.2* 248±32.1 
Doxorubicin control 64.5±11.2** 1025.7±154.3** -1031.1±159.4** 247±29.4 
Doxorubicin +exenatide (1 mcg/kg/day) 60.2±9.4** 1165.7±134.3** -1119.9±119.4** 232±29.4 
Doxorubicin +exenatide (10 mcg/kg/day) 76.8±7.4* 1302±169.2* -1157.4±137.3* 231±26.9 
Doxorubicin + vildagliptin  0.02 
mg/kg/day 
59.1±10.7** 1107.7±154.3** -984.9±129.1** 227±29.4 
Doxorubicin + vildagliptin  0.2 
mg/kg/day  
73.2±5.1* 1219±145.4* -1108±169.3* 232±36.1 
Note: LVL – left ventricular pressure (mmHg); + dp/dtmax – maximum contraction rate (mmHg/sec); -dp/dtmax maximum 
relaxation rate (mmHg/sec); HR – heart rate (bpm). Doxorubicin was administered intraperitoneally 48 hours before the 
experiment. The incretin mimetics  – exenatide and vildagliptin – were administered twice at an interval of 24 hours, 
respectively intramuscularly and intrahepatically. ** – p <0.005 in comparison with the group of intact animals *- p <0.005 in 
comparison with the control group. 
The ability of exenatide and vildagliptin to prevent 
damage to cell membranes was assessed by the change 
in the activity of CPK-MB and LDH in the perfusate 
during the reperfusion period (Figure 2, 3). 
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Fig.
 
2.
 
Content of  creatine phosphokinase
 
in the perfusate in groups under Exenatide (10 mcg/kg/day) and Vildagliptine 
(0.2 mg/kg/day) on the background of Doxorubicin myocardiopathy.
 
* 
– 
р< 0.05 in comparison with the control. 
** – р< 0.05  in comparison with the group of intact animals.
         Exenatide and vildagliptin contributed to a decrease in CPK-MB content by 45% and 30%, and in LDH – 36% and 24% 
compared to the control group. 
Fig. 3. Content of  lactate dehydrogenase in the groups under Exenatide (10 mcg/kg/day) and Vildagliptine  
(0.2 mg/kg/day) on the background of Doxorubicin myocardiopathy. * – р< 0.05 in comparison with the control. 
** – р< 0.05  in comparison with the group of intact animals 
Similar changes were observed in the markers of products of lipid peroxidation (Figure 4, 5). 
Fig. 4. Content of  malonic dialdehyde in the groups under Exenatide (10 mcg/kg/day) and Vildagliptine (0.2 mg/kg/day) 
on the background of Doxorubicin myocardiopathy. * – р< 0.05 in comparison with the control.  
** – р< 0.05  in comparison with the group of intact animals 
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Fig. 5. Content of  diene conjugates in the groups under Exenatide (10 mcg/kg/day) and Vildagliptine (0.2 mg/kg/day) 
on the background of Doxorubicin myocardiopathy.* – р< 0.05 in comparison with the control.  
** – р< 0.05  in comparison with the group of intact animals 
The formation of a highly active hydroxyl 
radical in the Huber-Weiss reaction involving 
superoxide dismutase and ferrous ions is one of the 
presumed causes of doxorubicin cardiomyopathy 
[25]. By influencing the exchange of iron: 
anthracyclines bind to Fe
2+
 ions, which leads to the 
formation of a hydroxyl radical, and promotes the 
release of Fe
2+
 ions from ferritin, further exacerbating 
oxidative stress [26]. 
Therefore, if the conditions for chelation or 
oxidation of ferrous ions Fe
2+
 in the catalytically 
inactive state of Fe
3+
 ions arise in the cytoplasm of 
cells, this will create the conditions for achieving 
micromolar concentrations of reactive oxygen 
species (ROS) in the cytoplasm of cells and reducing 
the damage to cardiomyocytes [27]. From the 
pharmacological point of view, antioxidants are of 
interest as one of the promising groups of 
cardioprotective drugs that allow to preserve a viable 
myocardium, limit the size of damage and accelerate 
the restoration of contractile activity of the 
myocardium [28, 29]. 
In incretins, the presence of one of the ways of 
realization of cardioprotective effect is described – 
the amplification of expression of heme-oxygenase-1 
(HO-1) [30]. This enzyme prevents the heme-
catalyzed formation of highly active hydroxyl 
radicals from hydrogen peroxide. Activation of 
heme-oxygenase-1 is associated with increased heme 
catabolism to bile pigments, which are potential 
endogenous antioxidants. In addition, induction of 
heme-oxygenase-1 is accompanied by an increase in 
ferritin activity, which has an antiapoptotic effect 
[31]. The enhancement of expression of heme-
oxygenase-1 under conditions of oxidative stress can 
play an adaptive role in response to oxidative damage 
and diminish the death of cardiomyocytes. 
The experimental studies demonstrate that when 
dosorubicin-induced cardiomyopathy is modeled in 
transgenic mice and animals with overexpression of 
HO-1, cardiac-specific hyperexpression of HO-1 
prevents doxorubicin-mediated damage of 
sarcoplasmic reticulum and mitochondria in 
autophagic vacuoles [32]. Overexpression of HO-1 
promotes mitochondrial biogenesis by enhancing the 
expression of the protein of the nuclear respiratory 
factor (NRF1), the coactivator (PGC1α) and the 
mitochondrial transcription factor (TFAM) that are 
inhibited in transgenic animals with doxorubicin-
induced cardiomyopathy. Simultaneously, 
overexpression of HO-1 inhibits the enhancement of 
the mitochondrial fusion mediator (Fis1) and leads to 
an increase in the expression of the mediators of the 
synthesis of Mfn1 and Mfn2. This also prevents 
mutations in key mitochondria genes PINK1 and 
PARKIN and ensures their normal functioning. This 
proves that NO-1 plays an important role in 
protecting the heart from oxidative damage by 
affecting mitochondria [33]. It can be surmised from 
the above that the mechanisms of antioxidant defense 
expression may take part in the mechanism of the 
protective action of the incritinomimetics in 
doxorubicin myocardiopathy. 
Conclusion.  
Thus, the incretin mimetics  exenatide (10 
mcg/kg/day) and vildagliptin (0.2 mg/kg/day) in the 
doxorubicin cardiomyopathy model have a protective 
effect, which manifests itself in the prevention of 
development of the "diastole defect" in the high-
frequency cardiac stimulation of the isolated heart of 
rats, in a dicrease in the levels of CPK-MB and LDH 
damage markers, as well as in prevention of 
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accumulation of lipid peroxidation products of MDA 
and DC in the ventricular myocardium. 
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